ERCC5: The Exclusion Repair Cross-Complementation Group 5 Enigma

Target Name: ERCC5

NCBI ID: G2073

ERCC5: The Exclusion Repair Cross-Complementation Group 5 Enigma

ERCC5, or Excision Repair Cross-Complementation Group 5, is a protein that plays a crucial role in DNA repair and has been identified as a potential drug target in the field of cancer. This protein is an essential component of the DNA damage response, which is a series of cellular pathways that respond to DNA damage and ensure the integrity of the genetic material.

ERCC5 is a protein that is expressed in various tissues and is involved in the repair of a variety of DNA types, including double-strand breaks and single-strand breaks. It is a key player in the excision repair process, which is the process by which the double-strand break is removed and the two strands are joined back together.

One of the challenges in the study of ERCC5 is its complex structure. While it is known that ERCC5 is a protein that plays a crucial role in the DNA damage response, it is not clear exactly how it functions. This lack of understanding has made it difficult to develop effective drugs that target ERCC5.

Despite the challenges, researchers have made significant progress in the study of ERCC5. One of the most promising research findings is that ERCC5 is a protein that is expressed in various tissues, including the brain, heart, and gastrointestinal tract. This suggests that it may be a potential drug target for a variety of diseases, including cancer.

Another promising finding is that ERCC5 is involved in a variety of cellular processes, including cell division, DNA replication, and apoptosis. This suggests that it may be a potential drug target for diseases that are characterized by these processes, such as cancer.

In addition, researchers have identified a number of potential drug targets that are associated with ERCC5. These targets include the androgen receptor, the p53 tumor suppressor gene, and the cyclin D1 gene. Further research is needed to determine the full extent of the ERCC5 drug target network and to develop effective drugs that target these targets.

The potential drug targets for ERCC5 are vast and varied. While it is important to continue studying its role in the DNA damage response and its potential drug targets, it is also important to consider the potential implications of its role in human disease.

In conclusion, ERCC5 is a protein that is involved in the DNA damage response and has been identified as a potential drug target for a variety of diseases. Further research is needed to fully understand its role in the DNA damage response and to develop effective drugs that target it.

Protein Name: ERCC Excision Repair 5, Endonuclease

Functions: Single-stranded structure-specific DNA endonuclease involved in DNA excision repair (PubMed:8206890, PubMed:8090225, PubMed:8078765, PubMed:7651464, PubMed:32821917, PubMed:32522879). Makes the 3'incision in DNA nucleotide excision repair (NER) (PubMed:8090225, PubMed:8078765, PubMed:32821917, PubMed:32522879). Binds and bends DNA repair bubble substrate and breaks base stacking at the single-strand/double-strand DNA junction of the DNA bubble (PubMed:32522879). Plays a role in base excision repair (BER) by promoting the binding of DNA glycosylase NTHL1 to its substrate and increasing NTHL1 catalytic activity that removes oxidized pyrimidines from DNA (PubMed:9927729). Involved in transcription-coupled nucleotide excision repair (TCR) which allows RNA polymerase II-blocking lesions to be rapidly removed from the transcribed strand of active genes (PubMed:16246722). Functions during the initial step of TCR in cooperation with ERCC6/CSB to recognized stalled RNA polymerase II (PubMed:16246722). Also, stimulates ERCC6/CSB binding to the DNA repair bubble and ERCC6/CSB ATPase activity (PubMed:16246722). Required for DNA replication fork maintenance and preservation of genomic stability (PubMed:26833090, PubMed:32522879). Involved in homologous recombination repair (HRR) induced by DNA replication stress by recruiting RAD51, BRCA2, and PALB2 to the damaged DNA site (PubMed:26833090). During HRR, binds to the replication fork with high specificity and stabilizes it (PubMed:32522879). Also, acts upstream of HRR, to promote the release of BRCA1 from DNA (PubMed:26833090)

More Common Targets